Business Wire

Enhancing the HD-PLC™ Security Functions

Share

HD-PLC Alliance *1 has started standardization work that will allow the use of enhanced network security functions, with the aim of using High-Definition Power Line Communication technology in the fields of smart grids and distributed power management.

HD-PLC™*2 (hereinafter referred to as HD-PLC) technology has already been standardized as IEEE 1901 (Broadband over Power Line Networks for MAC and PHY) by the IEEE Standards Association*3 . This technology is particularly attracting attention in Europe as a communication infrastructure that can be used for distributed power management of energy. Therefore, the current security functions will be enhanced and expanded, including making the technology compatible with strong authentication functions required for use in large-scale networks. Current HD-PLC technology offers extremely high security at the device level, including continuous encrypted communication and authentication between compatible devices. However, for PLC equipment to be used in large-scale systems, it must support various advanced security requirements required from the network operation side. The IEEE Standards Association established a new project called IEEE P1901b*4 in September this year to create specifications for this purpose, and held the first working group meeting this month. HD-PLC Alliance plays a central role in the development of these specifications in collaboration with member companies and system integrators.

Last year, HD-PLC Alliance led the development of the IEEE 1901a standard, a next-generation HD-PLC specification for the Internet of Things (IoT). This standard attracts attention because it defines a communication infrastructure technology for IoT services that are becoming more and more widespread. The security functions that will be enhanced as part of the IEEE P1901b project will greatly contribute to improve the safety not only of the aforementioned large-scale systems, but also of IoT networks that use IEEE 1901a in places such as offices, and factories.

In addition, by creating an international standard, it is expected that this communication technology will be used more and more not only on power lines, but also on all types of metallic wires and coaxial cables. Furthermore, it is hoped that the increased distance and speed of communication that will become possible through the use of this technology will accelerate the use of IoT communications. This includes building large-scale networks that cover not only living spaces but also social infrastructure such as office buildings and factories.

In addition to the communication compatibility certification services it currently implements for the third-generation of HD-PLC Complete specifications, for HD-PLC inside, and for the international standard ITU-T G.9905 on multi-hop functions, HD-PLC Alliance will continue to promote HD-PLC technology by creating new standards for next generations and expanding test environments and certification logos to certify the interconnection of HD-PLC devices compliant with the IEEE 1901 standard.

   

*1:

HD-PLC Alliance: Established on September 25, 2007 with the aim of expanding the use of High-definition Power Line Communication (HD-PLC) and ensuring communication compatibility.

   

*2:

HD-PLC™: A registered trademark or trademark of Panasonic Corporation in Japan and other countries.

   

*3:

IEEE Standards Association: Standards association within the Institute of Electrical and Electronics Engineers (IEEE)

   

*4:

IEEE P1901b: IEEE Standard for Broadband over Power Line Networks: Medium Access Control and Physical Layer Specifications –

   

 

Amendment: Enhancements for Authentication and Authorization

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

HD-PLC Alliance
Takanori Miyake, Ryoji Kido,
E-mail: info@hd-plc.org

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release

BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical

Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release

AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th

CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release

Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi

Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release

Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood

Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release

Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye